title: In vitro effects of meloxicam on metabolism in articular chondrocytes from dogs with naturally occurring osteoarthritis.
abstract: OBJECTIVE
  To assess effects of in vitro meloxicam exposure on metabolism in articular chondrocytes from dogs with naturally occurring osteoarthritis.
  
  
  METHODS
  Femoral head cartilage from 16 dogs undergoing total hip replacement.
  
  
  METHODS
  Articular cartilage samples were obtained. Tissue sulfated glycosaminoglycan (SGAG), collagen, and DNA concentrations were measured. Collagen, SGAG, chondroitin sulfate 846, NO, prostaglandin E2 (PGE2), and matrix metalloproteinase (MMP)-2, MMP-3, MMP-9, and MMP-13 concentrations in culture medium were analyzed. Aggrecan, collagen II, MMP-2, MMP-3, MMP-9, MMP-13, ADAM metallopeptidase with thrombospondin type 1 motif (ADAMTS)-4, ADAMTS-5, tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2, TIMP-3, interleukin-1β, tumor necrosis factor-α, cyclooxygenase-1, cyclooxygenase-2, and inducible nitric oxide synthase gene expression were evaluated. Comparisons between tissues cultured without (control) and with meloxicam at concentrations of 0.3, 3.0, and 30.0 μg/mL for up to 30 days were performed by means of repeated-measures analysis.
  
  
  RESULTS
  Meloxicam had no effect on chondrocyte SGAG, collagen, or DNA concentrations. Expression of ADAMTS-5 was significantly decreased in all groups on all days, compared with the day 0 value. On day 3, culture medium PGE2 concentrations were significantly lower in all meloxicam-treated groups, compared with values for controls, and values remained low. Culture medium MMP-3 concentrations were significantly lower on day 30 than on day 3 in all meloxicam-treated groups.
  
  
  CONCLUSIONS
  Results suggested that in vitro meloxicam treatment of osteoarthritic canine cartilage for up to 30 days did not induce matrix degradation or stimulate MMP production. Meloxicam lowered PGE2 release from this tissue, and effects on tissue chondrocyte content and matrix composition were neutral.
authors: Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA. budsberg@uga.edu
authors: Steven C
authors: SC
authors: Budsberg
authors: Aaron M
authors: AM
authors: Stoker
authors: Spencer A
authors: SA
authors: Johnston
authors: William
authors: W
authors: Liska
authors: Lisa R
authors: LR
authors: Reno
authors: James L
authors: JL
authors: Cook
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D002358:Cartilage, Articular / Q000166:cytology / Q000378:metabolism / Q000503:physiopathology*; D019902:Chondrocytes / Q000187:drug effects / Q000378:metabolism; D003094:Collagen / Q000235:genetics / Q000378:metabolism; D004283:Dog Diseases / Q000188:drug therapy / Q000503:physiopathology*; D004285:Dogs; D005260:Female; D006025:Glycosaminoglycans / Q000235:genetics / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D020782:Matrix Metalloproteinases / Q000235:genetics / Q000378:metabolism; D000077239:Meloxicam; D010003:Osteoarthritis / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary*; D012313:RNA / Q000737:chemistry / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction / Q000662:veterinary; D013843:Thiazines / Q000494:pharmacology* / Q000627:therapeutic use; D013844:Thiazoles / Q000494:pharmacology* / Q000627:therapeutic use; D019714:Tissue Inhibitor of Metalloproteinases / Q000235:genetics / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D006025:Glycosaminoglycans; D013843:Thiazines; D013844:Thiazoles; D019714:Tissue Inhibitor of Metalloproteinases; C013786:A73025; D012313:RNA; D003094:Collagen; D020782:Matrix Metalloproteinases; D000077239:Meloxicam